Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:57:25.561Z.
Calculation as of: 2026-10-06T16:57:25.561Z.
Quote observation: 2026-10-06T16:55:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: acb65a17080c98cb556e8dedfcd99ff418fc0d96cba63b9d245ba9f7ac680701
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$12.37M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.12M
EV/EBIT Ratio
N/A
TTM Avg
1095.87x
3Y Avg
388.61x
5Y Avg
279.45x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $12.44M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.37M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 1095.87x | 388.61x | 279.45x |
| Passage Bio, Inc. (PASG)vs › | $13.24M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.51M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.61M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.46M | N/A | 13.02x | 13.02x | 13.02x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
